A randomized trial to assess the biological activity of short-term (pre-surgical) fulvestrant 500 mg plus anastrozole versus fulvestrant 500 mg alone or anastrozole alone on primary breast cancer.
about
The ALTERNATE trial: assessing a biomarker driven strategy for the treatment of post-menopausal women with ER+/Her2- invasive breast cancerFulvestrant treatment alters MDM2 protein turnover and sensitivity of human breast carcinoma cells to chemotherapeutic drugsKnockdown of the Inhibitor of Apoptosis BRUCE Sensitizes Resistant Breast Cancer Cells to Chemotherapeutic AgentsBiological effects of fulvestrant on estrogen receptor positive human breast cancer: short, medium and long-term effects based on sequential biopsies.IPET study: an FLT-PET window study to assess the activity of the steroid sulfatase inhibitor irosustat in early breast cancer.Development of a Ki-67-based clinical trial assay for neoadjuvant endocrine therapy response monitoring in breast cancer.Fulvestrant plus targeted agents versus fulvestrant alone for treatment of hormone-receptor positive advanced breast cancer progressed on previous endocrine therapy: a meta-analysis of randomized controlled trials.Randomized phase 2 neoadjuvant trial evaluating anastrozole and fulvestrant efficacy for postmenopausal, estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients: Results of the UNICANCER CARMINA 02 FrenchClinical utility of fulvestrant in the treatment of breast cancer: a report on the emerging clinical evidence
P2860
Q26786704-6F0C198F-E057-4268-A935-6D7606E5A45BQ33880170-6FF2881D-1E41-4AF6-B2FA-C1C42C9D1A24Q35857227-4144FFB5-C0EA-4E4D-9C49-57CB7B958479Q36933778-F174713D-C7FD-4855-B0F1-CD92D8C96C0EQ38631164-459BEF9A-D513-4181-80A0-9B1F16B7E50DQ38726645-A2BF2557-459C-46E0-AD62-CB606757CDD0Q39190569-58BBA6CB-EA58-488D-AC74-722AF93E70E9Q51697267-8D081F3A-A63A-4259-8AD2-F9950897ADE3Q57107345-65485063-2253-425F-BB53-8D54369DDCCD
P2860
A randomized trial to assess the biological activity of short-term (pre-surgical) fulvestrant 500 mg plus anastrozole versus fulvestrant 500 mg alone or anastrozole alone on primary breast cancer.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
A randomized trial to assess t ...... lone on primary breast cancer.
@en
type
label
A randomized trial to assess t ...... lone on primary breast cancer.
@en
prefLabel
A randomized trial to assess t ...... lone on primary breast cancer.
@en
P2093
P2860
P356
P1476
A randomized trial to assess t ...... alone on primary breast cancer
@en
P2093
D Mark Sibbering
Eddie Channon
J Michael Dixon
John F R Robertson
Pauline Hyman-Taylor
Robert I Nicholson
P2860
P2888
P356
10.1186/BCR3393
P577
2013-03-05T00:00:00Z
P5875
P6179
1004787049